Risk Stratification and Adjuvant Chemotherapy for High-Risk Stage IA Lung Adenocarcinoma: The Unmet Needs.

Similarly, patients with ALK fusion also showed a trend towards reduced survival (5‐year RFS, ALK fusion vs. wild‐type, 66.3% vs. 73.6%, p = 0.404) (Figure 4B ). 4 Discussion This real‐world study of stage IA patients with at least 5% high‐grade subtypes revealed the complex landscape of managing postoperative adjuvant therapy in early‐stage LUAD.

also in 53,322 other papers